Analysts continue to bless the shares and offer tempting price targets. In November, Goldman Sachs said shares were worth $130, citing higher sales of Kyprolis. Deutsche Bank thinks Amgen shares are worth $138. The bank believes the buyout of Onyx will add 20% to earnings per share annually beginning in 2016.
While I ended up being right that Onyx would get acquired, I think the acquirer, Amgen, is just as good of a pick for 2014.
At the time of publication, the author had no position in any of the stocks mentioned.
This article represents the opinion of a contributor and not necessarily that of The Street or its editorial staff.